Research Dispatch

A systematic review and meta-analysis of RCTs evaluated polyphenolic compounds (the same family as green tea catechins/EGCG) for hair regeneration across non-scarring alopecia. It upgrades the natural-inhibitor category from mostly in-vitro mechanistic data to pooled human-trial evidence — supporting the green tea rule with modern, higher-grade data.

A systematic review and network meta-analysis compared dietary supplements for androgenetic alopecia directly against each other and placebo. It gives the supplement stack — pumpkin seed oil, saw palmetto, and related options — a single evidence-ranked comparison rather than isolated studies, which is exactly the data the protocol's ranked stack was built on.

A randomized comparison of oral finasteride versus dutasteride in men with moderate-to-severe androgenetic alopecia assessed trichoscopic and laboratory outcomes. It adds direct, contemporary head-to-head data to the existing systematic-review comparison — both drugs work, and the choice comes down to suppression depth versus side-effect duration.

A systematic review specifically examined sexual dysfunction associated with 5α-reductase inhibitors used for androgenetic alopecia. It keeps the risk conversation honest and current: side effects occur in a minority of users and typically resolve on discontinuation — but they are real, and the FAQ's physician-discussion recommendation stands on this class of evidence.

A large retrospective TriNetX cohort study found no increased cardiovascular hazard associated with oral 5-alpha-reductase inhibitors in androgenetic alopecia treatment. Reassuring for the long-horizon use the protocol discusses — while remaining observational, so it complements rather than replaces RCT safety data.

A systematic review and meta-analysis of RCTs assessed vitamin D supplementation's effect on total testosterone and androgen bioavailability markers in adult men. It upgrades the D3 + K2 stack entry from a single RCT and observational associations to pooled randomized evidence — a meaningful accuracy improvement for one of the protocol's five supplements.

A meta-analysis of 7 RCTs (N=396) found topical minoxidil + finasteride significantly outperformed minoxidil alone, with no treatment-emergent sexual side effects. Plasma finasteride stayed below 1 ng/mL — under the level linked to sexual dysfunction.

A systematic review found dutasteride 0.5–2.5 mg produced 90–110% greater hair-count increases than finasteride 1 mg, via dual Type 1+2 inhibition (~90% DHT suppression vs ~70%). Adverse-event rates were comparable — but dutasteride's ~5-week half-life (vs finasteride's 6–8 hours) means any side effects could linger longer.

A review of 9 studies found saw palmetto improved overall hair quality in 60% of users and raised total count by 27% — but it was inferior to finasteride in the only head-to-head, and the authors stress robust data are lacking. A separate RCT of 76 men found pumpkin seed oil (400 mg/day) beat placebo at 24 weeks. A reasonable mild, low-risk option — not a finasteride replacement.

A meta-analysis found the degree of weight loss was the best predictor of testosterone rise, via either low-calorie diet or bariatric surgery. The flip side: a chronic caloric deficit suppresses testosterone — under starvation the body deprioritizes reproduction. If you're cutting, do it in phases, not indefinitely.

The enzymes that activate vitamin D are magnesium-dependent, so correcting low magnesium improves vitamin D status and metabolism (RCT evidence). Practically: D3 alone can fall flat in men low on magnesium. Zinc is the mirror image — necessary for testosterone, but >40 mg/day long-term drives copper deficiency, which harms testosterone and immunity. Test, then correct; don't megadose.

From the supplement-composition literature: maca enhances libido but does not change testosterone; D-aspartic acid showed an early rise at 2.66 g/day that later studies failed to replicate — one 2017 trial found a decrease at 6 g/day. Ashwagandha, fenugreek, and DHEA show modest effects, mostly only when you're deficient. Test before you stack.

Across 33 pooled studies, oral dutasteride 0.5 mg/day ranked as the single most effective treatment. Among FDA-approved options, topical minoxidil 5% and oral finasteride 1 mg/day remain first-line. Topical finasteride 0.25% reduced scalp DHT comparably to oral, with potentially lower systemic exposure.

Low-dose oral minoxidil produced terminal-hair-density gains on par with topical 5%. The trade-off is systemic: unwanted hair growth (hypertrichosis) was far more common.

In a Korean cohort followed for five years, finasteride improved hair in 85.7% of patients and dutasteride in 89.9%. A newer lower-dose 0.2 mg dutasteride formulation (2024) showed non-inferior efficacy with fewer reported sexual side effects than the 0.5 mg dose.

Across comparative trials, plant-derived 5α-reductase inhibitors (saw palmetto, pumpkin seed oil) showed roughly ~30% of the effect seen with finasteride's ~70% at best. They are a milder, lower-risk option — not an equivalent substitute. We grade them honestly on the supplement page.

NHANES data (1999–2016) show total testosterone in men aged 15–39 dropping from 605 to 451 ng/dL. The decline runs ~0.56%/year and persists after controlling for aging, obesity, and assay differences — pointing to lifestyle and environmental drivers.

An Air Force veterans cohort (1982–2002) saw mean total testosterone fall from 638 to 431 ng/dL. Danish and Finnish cohorts born later in the 20th century also measured significantly lower than their predecessors — the decline replicates across countries.

In young healthy men, a single week of sleep restriction lowered daytime testosterone by 10–15%; 24 hours of total deprivation dropped it 25–30%. Fragmentation matters as much as duration — broken sleep blunts the overnight testosterone surge. The single most controllable lever on this list.

A study of 50 young men found hypertrophy training (β=20.3), >60 min/day sunlight (β=10.3), and a non-vegetarian diet (β=8.7) associated with higher testosterone. Negatives: under-6h sleep (β=−18.2), tobacco (β=−15.6), junk food (β=−14.5), carbonated drinks (β=−10.2). BMI was not significant in this young cohort. Small, observational — directional, not definitive.

Phthalates, BPA, PFAS, microplastics, air pollution (PM2.5), and pesticides (atrazine, glyphosate) are associated with reduced testosterone — reviews cite up to ~35% reduction potential, with some pesticides shown to directly inhibit Leydig-cell synthesis. These are correlational and exposure-dependent, not a verdict on any individual. Reducing plastic food contact and processed exposure is low-risk and sensible.

Reviews report opioids suppressing testosterone by nearly 50% via GnRH inhibition; statins lowering total T modestly (~0.66 nmol/L); and SSRIs and glucocorticoids interfering with the hormonal axis. This is information for a conversation with your doctor — not a reason to discontinue prescribed medication. Obesity remains a major driver (BMI >35–40 linked to up to 50% lower T), though stable-weight men still declined ~19% over 20 years.

A PubMed audit of T-booster supplements found only 24.8% had any data supporting an increase, 61.5% had no published data at all, and 18.3% were associated with a decrease. The FDA has issued warnings for products containing hidden steroids. Vitamin D (when deficient) and ashwagandha have the most credible signals; we grade each on evidence quality, not hype.